Meningococcal Vaccines April 2025
There are three types of meningococcal vaccines licensed by the U.S. Food and Drug Administration (FDA): Meningococcal conjugate (MenACWY) in 2005 and Serogroup B meningococcal (MenB) vaccines in 2015. According to the U.S. CDC, about 88% of adolescents aged 13–17 had received at least one MenACWY dose.
Internationally, the European Medicines Agency (EMA) and the U.K. NHS have approved vaccines such as MenQuadfi and Hib/MenC. The Global Roadmap for Defeating Meningitis by 2030 was endorsed by the World Health Assembly and launched in 2021. According to a research report published in 2022, the meningococcal vaccine market is expected to reach approximately U.S. $5.91 billion by 2030.
Quadrivalent Meningococcal Conjugate (MenACWY) Vaccines
Menactra vaccine is for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals nine months through 55 years of age.
Menveo® vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. It is approved for use in people aged two months through 55.
MenQuadfi® vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for those two years of age and older.
Serogroup B Meningococcal (MenB) Vaccines
Trumenba vaccine is used for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for individuals aged 10-25 years.
Bexsero® is a vaccine against Neisseria meningitidis serogroup B, which causes invasive diseases. The vaccine was approved for use in 2015 for individuals aged 10 through 25.
Two additional licensed meningococcal vaccines are no longer available in the United States: 1) a quadrivalent (serogroups A, C, W, and Y) meningococcal polysaccharide vaccine (MPSV4) (Menomune – A/C/Y/W-135) and 2) a combined Haemophilus influenzae type b and meningococcal serogroups C and Y conjugate vaccine (Hib-MenCY-TT) (MenHibrix).
Meningococcal Pentavalent Vaccines
GlobalData projects the collective revenue for pentavalent vaccines to reach approximately $555 million in the U.S. by 2029.
Pfizer Inc.'s PENBRAYA™ (meningococcal groups A, B, C, W, and Y vaccine) is a pentavalent vaccine that combines the components from two meningococcal vaccines, Trumenba® (meningococcal group B vaccine) and Nimenrix® (meningococcal groups A, C, W-135, and Y conjugate vaccine), to help protect against the five most common meningococcal serogroups that cause the majority of M.D. globally. PENBRAYA is administered as a two-dose series given six months apart. On October 25, 2023, Jennifer Collins, MD, MSc, presented a Summary of EtR and proposed recommendations for Pfizer's MenABCWY vaccine.
Serum Institute of India Pvt. Ltd. MenFive® (NmCV-5) is a pentavalent vaccine targeting the A, C, W, Y, and X serogroup. In July 2023, the WHO prequalified MenFive®. Nigeria became the first country in the world to offer the multivalent conjugate vaccine Men5CV. In September 2023. the WHO's SAGE then advised all countries in the meningitis belt to introduce the new vaccine, which it described as Men5CV, into their routine immunization programs.
GSK's PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine), for use in individuals aged 10 through 25, combines Bexsero (meningococcal group B vaccine) and Menveo (meningococcal group A, C, W-135, and Y conjugate vaccine). On April 15, 2025, the ACIP voted to recommend that persons over 10 years old receive a single dose.
